A Look Ahead to the Advanced Prostate Cancer Consensus Conference (APCCC 2019)
Urology News and Education Resource
Wednesday, 24 June 2026
Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin
Silke Gillessen, MD
Silke Gillessen, MD and Aurelius Omlin, MD discuss the inception of the biennial Advanced Prostate Cancer Consensus Conference (APCCC) which will be held in Basel this August. The intent of the meeting is to drive international consensus on key areas of prostate cancer practice where there are no clear guidelines or level 1 evidence. 75% of the panelists must agree on each topic to reach a consensus.
Looking Forward to the APCCC 2019 - Brenda Martone
Brenda Martone, MSN, ANP-BC, AOCNP
Alicia Morgans and Brenda Martone discuss the upcoming Advanced Prostate Cancer Consensus Conference (APCCC 2019). This global conference focuses on the grey areas where Level 1 Evidence is not available to guide treatment decisions in the clinic. Experts from around the globe will gather in Basel, Switzerland from August 28 - August 31 to discuss areas of controversy in the treatment of prostate cancer in 2019.
Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer
Michael Hofman, MBBS (Hons), FRACP, FAANMS
Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically.
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases
A. Oliver Sartor, MD
Neal Shore and Oliver Sartor discuss the role of both alpha and beta radiopharmaceuticals that are on the horizon for treatment of bone metastases in prostate cancer. Dr. Sartor reviews the compelling data for the use radium-223 with respect to the improvement seen in overall survival along with additional alpha targeted agents that are on the horizon.
Thursday, 29th August
9:15 - 10:45 | Session 1 Molecular biomarkers and novel imaging in APC
State of the art on molecular characterization in APC
Advantages and pitfalls of PSMA PET/CT in APC imaging
11:15 – 12:45 | Session 2 Node-positive prostate cancer (N1 but M0)
How to treat men with newly diagnosed cN1 cM0 Surgery Options RadiationTherapy Options Systemic therapy options
1:45 – 3:15 | Session 3 PSA recurrence after radical local therapy and oligometastatic prostate cancer
Management of men with PSA recurrence after radical local radiation therapy
Management of men with PSA recurrence or persistence after prostatectomy
Treatment of oligometastatic and oligoprogressive CRPC
3:45 – 5:15 | Session 4 Disparities in prostate cancer management in the U.S.
Friday, 30th August
8:00 - 8:30 | Extra Session
Movember Session
Outcomes Research – Ironman project
8:30 - 10:15 | Session 5 Management of metastatic castration-sensitive/naive prostate cancer
Which systemic therapy for which patient with newly diagnosed metastatic prostate cancer?
Addition of AR pathway inhibitors vs. docetaxel: Statisticians’ perspective
Follow-up on ADT alone vs. ADT “plus”
10:45 – 12:45 | Session 6 Management of castration-resistant prostate cancer (CRPC)
Debate: Treatment of nmCRPC
First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor
Subgroup analysis of mCRPC clinical trials
PSMA targeted therapies PARP inhibition
3:15 – 4:45 | Session 8 Bone and bone metastases Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC Radium-223 and bone health agents
You are receiving this email because you have chosen to receive emails from UroToday...
